This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (44)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Randomized Controlled Trial  • Articles for Residents  • Glaucoma  • Ophthalmological Disorders, Other  • Drug Therapy  • Alert me on articles by topic

One-Year Randomized Trial

Eve J. Higginbotham, MD; Robert Feldman, MD; Michael Stiles, MD; Harvey Dubiner, MD; for the Fixed Combination Investigative Group

Arch Ophthalmol. 2002;120:915-922.

Objective  To compare the efficacy and safety of a fixed combination of 0.005% latanoprost and 0.5% timolol maleate administered once daily vs monotherapy with either 0.005% latanoprost once daily or 0.5% timolol twice daily.

Methods  Patients with either primary or secondary open-angle glaucoma or ocular hypertension participated in a 6-month, randomized, double-masked, multicenter study with 3 parallel treatment groups. The double-masked period was preceded by a 2- to 4-week "run-in" treatment with timolol. Subjects could receive fixed combination therapy during a 6-month open-label extension.

Main Outcome Measure  The difference between groups in mean diurnal intraocular pressure reduction in study eye(s) from baseline through 6 months of treatment.

Results  Overall, 418 patients were enrolled in the study; 332 completed the open-label phase. Diurnal intraocular pressure levels were similar at baseline, but at week 26, they were 19.9 ± 3.4 mm Hg in the fixed combination therapy group, 20.8 ± 4.6 mm Hg in latanoprost-treated patients, and 23.4 ± 5.4 mm Hg in timolol-treated patients (data are given as mean ± SD). The mean change from baseline was greater among patients receiving fixed combination therapy compared with each monotherapy group (P<.01). Fixed combination therapy effectively lowered intraocular pressure levels for up to 1 year. All treatments were well tolerated.

Conclusion  The combination of 0.005% latanoprost and 0.5% timolol administered once daily is effective and well tolerated for up to 12 months.

From the Department of Ophthalmology, The University of Maryland School of Medicine, Baltimore (Dr Higginbotham), and the Department of Ophthalmology and Visual Sciences, The University of Texas–Houston Medical School (Dr Feldman). Drs Stiles and Dubiner are in private practice in Kansas City, Mo, and Morrow, Ga, respectively.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

24-Hour Control With a Latanoprost-Timolol Fixed Combination vs Timolol Alone.
Konstas et al.
Arch Ophthalmol 2006;124:1553-1557.
ABSTRACT | FULL TEXT  

Twice-Daily 0.2% Brimonidine-0.5% Timolol Fixed-Combination Therapy vs Monotherapy With Timolol or Brimonidine in Patients With Glaucoma or Ocular Hypertension: A 12-Month Randomized Trial.
Sherwood et al.
Arch Ophthalmol 2006;124:1230-1238.
ABSTRACT | FULL TEXT  

Twenty-four-Hour Control With Latanoprost-Timolol-Fixed Combination Therapy vs Latanoprost Therapy
Konstas et al.
Arch Ophthalmol 2005;123:898-902.
ABSTRACT | FULL TEXT  

Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies
Hamacher et al.
Br. J. Ophthalmol. 2004;88:1295-1298.
ABSTRACT | FULL TEXT  

A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension
Diestelhorst and Larsson
Br. J. Ophthalmol. 2004;88:199-203.
ABSTRACT | FULL TEXT